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GUEST EDITORIAL
Breast cancer: the obesity connection
B.A. Stoll
Oncology Department, St. Thomas' Hospital, London SE] 7EH, UK.
Breast cancer risk is increased up to 50% in the presence of
obesity as measured by weight/height or body mass index,
but only in the case of post-menopausal women. Obese
premenopausal women show either an unchanged or de-
creased risk (Albanes, 1987; London et al., 1989). The in-
creased risk of breast cancer in obese post-menopausal
women is usually ascribed to excess oestrogen derived from
aromatisation of androgen in peripheral fat deposits
(Kampert et al., 1988; De Waard, 1991). Research on the
link between obesity and breast cancer risk has recently
centred on fat-distribution patterns in women. Several case-
control studies have shown an increased breast cancer risk in
post-menopausal women with abdominal-type obesity, defined
as a high waist/hip circumference ratio (Ballard-Barbash et
al., 1990; Berstein, 1990; Folsom et al., 1990; Schapira et al.,
1990; Kodama et al., 1991; Briining et al., 1992), although
not all agree (Lapidus et al., 1988; Petrek et al., 1993).
Women with this so-called male pattern of obesity charac-
teristically show excess circulating levels of testosterone and
hyperinsulinaemia (Evans et al., 1983; Kissebah & Peinis,
1989; Kirschner et al., 1990; Schapira et al., 1991). A variety
of possible mechanisms has been proposed for the increased
breast cancer risk observed in post-menopausal women with
abdominal-type obesity (Sellers et al., 1992a).
1. Increased oestradiol levels resulting from aromatisation of
excess circulating androgen to oestrogen.
2. Increased free oestradiol levels resulting from decreased
levels of sex hormone-binding globulin (SHBG), which are
commonly associated with abdominal-type obesity.
3. Direct androgenic stimulation of mammary tissue activity
after binding to androgen receptors.
4. Synergism between sex steroids and insulin-like growth
factor (IGF-1), leading to stimulation of proliferative
activity in mammary epithelium in a subset of women.
Excess circulating levels of androgen are unlikely to con-
tribute significantly to oestrogenic stimulation of car-
cinogenesis, as only a very small fraction of androgen is
converted to oestrogen. There is also no evidence in the
human that the activity of breast tissue is influenced by
androgen acting through androgen receptor. On the other
hand, the fourth of the mechanisms suggested is favoured by
recent reports that hyperinsulinaemia (Briining et al., 1992),
increased IGF-1 levels (Peyrat et al., 1993) and excess and-
rogen levels (Secreto et al., 1989, 1991) are markers for
increased breast cancer risk in both pre- and post-
menopausal women. It also offers an explanation for the
observation that abdominal-type obesity is not a risk marker
for breast cancer in premenopausal women (Stoll, 1993).
Insulin has long been known to stimulate proliferative
activity of mammary epithelium in vitro, but its major
growth-promoting effect in vivo is likely to be through IGF-1.
Circulating IGF-1 levels are mainly regulated by growth
hormone, but insulin also plays a part in this, in addition to
regulating hepatic production of IGF-1-binding proteins
(Cotterill et al., 1992). IGF-1 is a potent mitogen for human
mammary cancer cells in vitro and may either substitute for,
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or mediate the effect of, oestrogen (Macaulay, 1992). In fresh
breast cancer tissue, oestrogen receptor expression is
positively correlated with IGF-1 receptor expression (Peyrat
et al., 1988).
The pattern of IGF-binding proteins in mammary cells
may determine their mitogenic response to IGF derived from
adjacent stromal cells (Cullen et al., 1991). Women with
abdominal-type obesity show lower levels of IGFBP-1 and
higher insulin levels than do those with lower body-type
obesity (Conover et al., 1992). Thus, it has been variously
suggested that proliferative activity in normal and malignant
mammary tissue might be stimulated through increased pro-
duction of IGF-1, overexpression of IGF-1 receptors (Kaleko
et al., 1990) or changes in the level of IGF-binding proteins
(McGuire et al., 1992).
The mechanism causing excess androgen levels in insulin-
resistant states is not clear, but hyperinsulinaemia is likely to
be the primary factor (Kirschner et al., 1990). Increased
plasma insulin levels in pre- and post-menopausal women are
associated with a stepwise decrease in plasma SHBG levels,
and this relationship is independent of age and obesity
(Preziosi et al., 1993). A decrease in SHBG levels causes a
rise in free concentrations of both testosterone and oest-
radiol, but because the affinity of SHBG is greater for tes-
tosterone than for oestradiol, there is a shift of the relative
androgen/oestrogen balance towards androgen. Another pos-
sible cause of excess androgen levels is that insulin and
IGF-1 can modulate steroid hormone biosynthesis and
clearance in the ovary and adrenal cortex (Nestler & Strauss,
1991). Whatever its origin, excess androgen is thought to
trigger the appearance of abdominal-type obesity in women
with a genetic susceptibility. The presence of excess androgen
is thought to direct depot fat to the abdomen rather than to
the femoral-gluteal region (Evans et al., 1983).
Excess testosterone in itself is not necessarily an
aetiological factor in mammary carcinogenesis, but its
aromatisation to oestrogen in breast fat may act synergis-
tically with local growth factors in stimulating hyperplasia in
mammary epithelium. High androgen levels have been sliown
to cause oestrogen-like stimulation in oestrogen target tissues
(Rochefort & Garcia, 1984). However, further evidence is
required, and not all studies confirm that excess androgen
levels are a risk marker for breast cancer. It is possible that
the class of androgen is important and that some studies
have not taken sufficient account of distinctions between pre-
and post-menopausal status.
We still need to explain why abdominal-type obesity is a
risk marker only in post-menopausal women. There is
evidence to suggest that excess androgen may favour car-
cinogenesis only in post-menopausal women because of the
clonal selection which occurs at the menopause. Changes in
the androgen/oestrogen ratio at critical times during the
growth or involution of mammary tissue may determine the
malignant potential (Bulbrook, 1991). The following observa-
tions suggest that menopausal changes which switch major
sex steroid production from the ovary to the adrenal cortex
may lead to overgrowth of cells more sensitive to androgen
stimulation.
1. Clonal selection is likely to operate in the progression
from epithelial atypia and carcinoma in situ to frank
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invasive cancer around the time of the menopause
(Howell, 1989). Practically all cells in the preinvasive
lesions are oestrogen receptor positive (Nenci et al., 1988).
The incidence of preinvasive lesions falls sharply at the
onset of the menopause (Nielsen et al., 1987), and only a
minority progress to invasive cancer, suggesting that the
menopausal change in sex steroid production selects
specific clones for growth.
2. Testosterone at physiological levels is reported to enhance
the growth of mammary cell lines derived from the
majority of a group of post-menopausal patients but not
from those of premenopausal patients (Simon et al.,
1984). This observation again suggests that clonal selec-
tion occurs at the menopause.
3. The response of advanced breast cancer to androgen
administration varies according to menopausal status. In
a survey of 521 treated patients, objective response to
testosterone propionate was noted in 8.7% of women
within a year following the menopause, in 17% of those
post-menopausal for 1-5 years, and in 26% of those
more than 5 years post-menopausal (Cooperative Breast
Cancer Group, 1964). On the other hand, of 22 pre-
menopausal patients treated by androgen, not a single
patient responded (Stoll, 1972).
What are the implications of the finding that abdominal-
type obesity in post-menopausal women is associated with
increased breast cancer risk? Observations on twins suggest
that genetic influences are involved in susceptibility to
abdominal-type obesity (Sims, 1990), but rich nutrition is
likely to be a triggering factor. It is reported (Sellers et al.,
1992a) that the increased breast cancer risk associated with
abdominal-type obesity is predominantly in women with a
family history of breast cancer. It cannot however be
assumed that abdominal-type obesity is genetically linked to
breast cancer susceptibility. It may merely provide a
metabolic/endocrine environment that favours promotion of
breast cancer growth in genetically susceptible women
(Sellers et al., 1992b).
It may be relevant that abdominal-type obesity, hyper-
insulinaemia and excess androgen levels are also markers for
the condition of non-insulin-dependent diabetes (NIDDM) in
Western women (Bjorntorp, 1988). Insulin resistance progres-
sing to hyperinsulinaemia is relatively common in obese
Western men and women (Moller & Flier, 1991) and even
20% of non-obese individuals show similar insulin resistance
as measured by the fasting plasma glucose/insulin ratio
(Caro, 1991). Hyperinsulinaemia has been shown to be
significantly more frequent among women with early breast
cancer than in women of the same age group with early
lymphoma, melanoma or cervical cancer, and it is suggested
that hyperinsulinaemia may represent a metabolic link
between the Western lifestyle and breast cancer risk (Bruning
et al., 1992). It is, however, plausible that clonal selection
after the menopause may be necessary for the androgenic
concomitant of insulin resistance to increase the risk. This
may explain why obesity in premenopausal women is not
found to be associated with increased breast cancer risk.
The suggestion that the concomitant of insulin resistance is
a risk marker for breast cancer needs to be tested in a large
group of early breast cancer cases. However, to establish a
causative role for the metabolic/endocrine abnormality, we
require evidence that it predates the manifestation of clinical
breast cancer. This hypothesis could be tested by looking for
abnormalities involving glucose tolerance, oestrogen/andro-
gen ratio or IGF-1 bioactivity in women showing evidence of
atypical hyperplasia or in situ cancer changes in breast biop-
sies. Apart from throwing light on mechanisms which may
help to promote mammary carcinogenesis, such investiga-
tions may provide non-invasive markers of an intermediate
stage in the development of breast cancer and may assist in
identifying women for trials of protective agents such as
tamoxifen.
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